MRVI

Maravai LifeSciences Holdings, Inc. Class A Common Stock

3.15

USD

MRVI Earnings Reports

Positive Surprise Ratio

MRVI beat 12 of 20 last estimates.

60%

Next Report

Date of Next Report

Feb 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

$50.03M

-$0.07

Implied change from Q3 25 (Revenue/ EPS)

+20.17%

-12.50%

Implied change from Q4 24 (Revenue/ EPS)

-11.55%

+16.67%

Maravai LifeSciences Holdings, Inc. Class A Common Stock earnings per share and revenue

On Nov 06, 2025, MRVI reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 3.96% surprise. Revenue reached 41.63 million, compared to an expected 49.98 million, with a -16.71% difference. The market reacted with a -0.69% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 50.03 million USD, implying an decrease of -12.50% EPS, and increase of 20.17% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Phibro Animal Health Corporation Class A

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.68

Actual

$0.87

Surprise

+27.30%

Canopy Growth Corporation Common Shares

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.04

Actual

-$0.13

Surprise

-198.00%

Aurora Cannabis Inc. Common Shares

Report Date

Feb 04, 2026 For Q3 26

Estimate

$0.21

Actual

$0.12

Surprise

-42.72%

High Tide Inc. Common Shares

Report Date

Jan 29, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.56

Surprise

0.00%

Stryker Corporation

Report Date

Jan 29, 2026 For Q4 25

Estimate

$4.43

Actual

$4.47

Surprise

+0.69%

Boston Scientific Corp.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.78

Actual

$0.80

Surprise

+1.61%

ResMed Inc.

Report Date

Jan 29, 2026 For Q2 26

Estimate

$2.75

Actual

$2.81

Surprise

+2.15%

GE HealthCare Technologies Inc. Common Stock

Report Date

Feb 04, 2026 For Q4 25

Estimate

$1.42

Actual

$1.44

Surprise

+0.96%

Envista Holdings Corporation Common stock, $0.01 par value per share

Report Date

Feb 05, 2026 For Q4 25

Estimate

$0.32

Actual

$0.38

Surprise

+15.43%

Prestige Consumer Healthcare Inc.

Report Date

Feb 05, 2026 For Q3 26

Estimate

$1.15

Actual

$1.13

Surprise

-1.36%

FAQ

What were Maravai LifeSciences Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Maravai LifeSciences Holdings, Inc. Class A Common Stock reported EPS of -$0.08, beating estimates by 3.96%, and revenue of $41.63M, -16.71% below expectations.

How did the market react to Maravai LifeSciences Holdings, Inc. Class A Common Stock's Q3 2025 earnings?

The stock price moved down -0.69%, changed from $2.89 before the earnings release to $2.87 the day after.

When is Maravai LifeSciences Holdings, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Feb 25, 2026.

What are the forecasts for Maravai LifeSciences Holdings, Inc. Class A Common Stock's next earnings report?

Based on 12 analysts, Maravai LifeSciences Holdings, Inc. Class A Common Stock is expected to report EPS of -$0.07 and revenue of $50.03M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.